Phase I trial of ZIO-101 [darinaparsin] in hematologic cancers
Latest Information Update: 11 Feb 2022
At a glance
- Drugs Darinaparsin (Primary)
- Indications Leukaemia; Lymphoma; Lymphoproliferative disorders; Multiple myeloma; Myeloproliferative disorders
- Focus Adverse reactions
- Sponsors Alaunos Therapeutics
- 18 Jul 2012 Actual end date changed from Jun 2006 to Jun 2008 as reported by ClinicalTrials.gov.
- 01 Jul 2009 Actual patient number (12) added as reported by ClinicalTrials.gov.
- 01 Jul 2009 Actual end date (Jun 2006) added as reported by ClinicalTrials.gov.